Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 17

1.

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1368-76. doi: 10.1007/s00259-009-1370-z. Epub 2010 Feb 13.

2.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

PMID:
16710024
3.

Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck.

Schechter NR, Wendt RE 3rd, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, Broemeling LD, Kim EE, Cox JD, Podoloff DA, Ang KK.

J Nucl Med. 2004 Oct;45(10):1683-7.

4.

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG.

Br J Pharmacol. 2004 Sep;143(1):99-106. Epub 2004 Aug 2.

5.

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

Gr├╝nwald V, Hidalgo M.

J Natl Cancer Inst. 2003 Jun 18;95(12):851-67. Review.

PMID:
12813169
6.

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.

Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R 3rd, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA.

Anticancer Drugs. 2003 Jan;14(1):49-56.

PMID:
12544258
7.

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L.

Cancer Res. 2002 Dec 15;62(24):7350-6.

8.
9.

Biology of HER2 and its importance in breast cancer.

Yarden Y.

Oncology. 2001;61 Suppl 2:1-13. Review.

PMID:
11694782
10.
11.

The basic biology of HER2.

Rubin I, Yarden Y.

Ann Oncol. 2001;12 Suppl 1:S3-8. Review.

PMID:
11521719
12.

Growth factor synthesis and human breast cancer progression.

Ethier SP.

J Natl Cancer Inst. 1995 Jul 5;87(13):964-73. Review.

PMID:
7629883
13.

Predictive value of EGF receptor in breast cancer.

Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U.

Lancet. 1988 Nov 26;2(8622):1258. No abstract available.

PMID:
2903994
14.

Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.

Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E.

Cancer Res. 1988 Jan 1;48(1):137-41.

15.

Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.

Mendelsohn J.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):889-92. Review.

PMID:
2285602
16.

Epidermal growth factor.

Carpenter G, Cohen S.

J Biol Chem. 1990 May 15;265(14):7709-12. Review. No abstract available.

17.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM.

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9.

Supplemental Content

Support Center